Cor Vasa 2020, 62(3):257-266 | DOI: 10.33678/cor.2019.082

Serum chemerin correlated to the SYNTAX score in obese Egyptian patients with coronary artery disease

Noha Hassanin, Yasser Sharaf, Mervat Al-Anany, Essam Faisal
Cardiology Department, Cairo University, Cairo, Egypt

Background: Chemerin is a newly discovered adipokine which has been found closely associated with obesity, metabolic syndrome, and inflammatory status. However, it remains unclear whether chemerin is involved in patients with cardiovascular disease.

Objective: The aim of the study was to examine whether serum chemerin levels are associated with the severity of coronary artery disease (CAD) in obese Egyptian patients.

Material and methods: The study enrolled 100 patients who underwent coronary angiography for clinically indicated reasons classified according to body mass index (BMI) into two groups, 50 patients (group A) with BMI (≥30 kg/m2) and 50 patients (group B) with BMI ≤25 kg/m2. Severity of CAD was estimated with SYNTAX score and serum chemerin level was measured using ELISA method.

Results: Serum chemerin level was higher in obese patients (p = 0.019), and it was positively correlated with SYNTAX score (r = 0.533, p <0.001), BMI, waist circumference, FPG, left ventricle mass index (LVMI) and high sensitivity C-reactive protein (hs-CRP) (p value <0.005 for all). Serum chemerin levels were significantly increased with an increasing number of diseased vessels (p = 0.013). At multiple linear regression analysis serum chemerin level was found to be an independent predictor of SYNTAX score (β = 0.432, p <0.001). Serum chemerin also was associated with LVH (p = 0.004) Conclusion: Serum chemerin levels were higher in obese patients and were associated with LVH and inflam- mation. Also it has a significant correlation with severity of coronary artery disease in Egyptian patients with coronary artery disease.

Keywords: Coronary artery disease, Serum chemerin, SYNTAX score

Received: January 9, 2019; Accepted: December 5, 2019; Published: July 29, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hassanin N, Sharaf Y, Al-Anany M, Faisal E. Serum chemerin correlated to the SYNTAX score in obese Egyptian patients with coronary artery disease. Cor Vasa. 2020;62(3):257-266. doi: 10.33678/cor.2019.082.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Poirier P, Giles T, Bray G, et al. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 2006;26:968-976. Go to original source... Go to PubMed...
    2. Iantorno M, Campia U, Di Daniele N, et al. Obesity, inflammation and endothelial dysfunction. J Biol Regul Homeost Agents 2014;28:169-176. Go to PubMed...
    3. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005;366:1640-1649. Go to original source... Go to PubMed...
    4. Finucane M, Stevens G, Cowan M, et al. National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011;377:557-567. Go to original source... Go to PubMed...
    5. Dickson A, Zacharie T, Blessing M, et al. Prevalence and time trends in overweight and obesity among urban women: an analysis of demographic and health surveys data from 24 African countries, 1991-2014. BMJ Open 2017;7:e017344. Go to original source... Go to PubMed...
    6. WHO. Physical Status: The Use and Interpretation of Anthropometry: Report of a World Health Organization (WHO) Expert Committee. Geneva, Switzerland: World Health Organization, 1995.
    7. Garrow J, Webster J. Quetelet's index (W/H2) as a measure of fatness. Int J Obes 1985;9:147-153.
    8. Liu J, Fox C, Hickson D, et al. Impact of abdominal visceral and subcutaneous adipose tissue on cardiometabolic risk factors: the Jackson Heart Study. J Clin Endocrinol Metab 2010;95:5419-5426. Go to original source... Go to PubMed...
    9. Tchernof A, Després J. Pathophysiology of human visceral obesity: an update. Physiol Rev 2013;93:359-404. Go to original source... Go to PubMed...
    10. Van de Voorde J, Pauwels B, Boydens C, Decaluwé K. Adipocytokines in relation to cardiovascular disease. Metabolism 2013;62:1513-1521. Go to original source... Go to PubMed...
    11. Bastien M, Poirier P, Lemieux I, Després J. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis 2014;56:369-381. Go to original source... Go to PubMed...
    12. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. Lancet 2004;364:937-952. Go to original source... Go to PubMed...
    13. Van Gaal L, Mertens I, De Block C. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875-880. Go to original source... Go to PubMed...
    14. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 2009;6:399-409. Go to original source... Go to PubMed...
    15. Musi N, Guardado-Mendoza R. Adipose Tissue as an Endocrine Organ. Cell Endocrinol Heal Dis 2014;(July 2004):229-237. Go to original source...
    16. Gray S, Vidal-Puig A. Adipose Tissue expandability in the maintenance of metabolic homeostasis. Nutr Rev 2007;65(6 Pt 2):S7-S12. Go to original source...
    17. Shibata R, Ouchi N, Ohashi K, Murohara T. The role of adipokines in cardiovascular disease. J Cardiol 2017;70:329-334. Go to original source... Go to PubMed...
    18. Mattu H, Randeva H. Role of adipokines in cardiovascular disease. J Endocrinol 2013;216:T17-T36. Go to original source... Go to PubMed...
    19. Ernst M, Sinal C. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab 2010;21:660-667. Go to original source... Go to PubMed...
    20. Nagpal S, Patel S, Jacobe H, et al. Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. J Invest Dermatol 1997;109:91-95. Go to original source... Go to PubMed...
    21. Sang H, Mi K, Ki Y, et al. Chemerin and adiponectin contribute reciprocally to metabolic syndrome. PLoS ONE 2012;7:e34710. Go to original source... Go to PubMed...
    22. Zabel B, Silverio A, Butcher E. Chemokine-Like Receptor 1 Expression and Chemerin-Directed Chemotaxis DistinguishPlasmacytoid from Myeloid Dendritic Cells in Human Blood. J Immunol 2005;174:244-251. Go to original source... Go to PubMed...
    23. Landgraf K, Friebe D, Ullrich T, et al. Chemerin as a mediator between obesity and vascular inflammation in children. J Clin Endocrinol Metab 2012;97:E556-E564. Go to original source... Go to PubMed...
    24. Yan Q, Zhang Y, Hong J, et al. The association of serum chemerin level with risk of coronary artery disease in Chinese adults. Endocrine 2012;41:281-288. Go to original source... Go to PubMed...
    25. Dong B, Ji W. Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with metabolic syndrome. Intern Med 2011;50:1093-1097. Go to original source... Go to PubMed...
    26. Inzucchi S, Bergenstal R, Buse J, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379. Go to original source... Go to PubMed...
    27. Shen W, Sheldon R, Benditt D, et al. 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. Circulation 2017;136:e60-e122. Go to original source...
    28. World Health Organization. Waist Circumference and Waist-Hip Ratio: Report of a WHO Expert Consultation. World Heal Organ 2008;( December):8-11.
    29. Sianos G, Morel M, Kappetein A, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005;1:219-227. Go to PubMed...
    30. Medina A, Suárez de Lezo J, Pan M. A new classification of coronary bifurcation lesions. Rev Esp Cardiol 2006;59:183. Go to original source...
    31. Carr D, Utzschneider K, Hull R, et al. Intra-abdominal fat is a major determinant of the National Cholesterol EducationProgram Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004;53:2087-2094. Go to original source... Go to PubMed...
    32. Lavie C, Milani R, Ventura H. Obesity and Cardiovascular Disease. Risk Factor, Paradox, and Impact of Weight Loss. J Am Coll Cardiol 2009;53:1925-1932. Go to original source... Go to PubMed...
    33. Hart R, Greaves DR. Chemerin Contributes to Inflammation by Promoting Macrophage Adhesion to VCAM-1 and Fibronectin through Clustering of VLA-4 and VLA-5. J Immunol 2010;185:3728-3739. Go to original source... Go to PubMed...
    34. Ali TM, Al Hadidi K. Chemerin is associated with markers of inflammation and predictors of atherosclerosis in Saudi subjects with metabolic syndrome and type 2 diabetes mellitus. Beni-Suef Univ J Basic Appl Sci 2013;2:86-95. Go to original source...
    35. Ashutosh N, Jyotiranjan P, Hesham F, et al. Severity of Coronary Artery Disease in Obese Patients Undergoing Coronary Angiography: Obesity Paradox Revisited. Clin Cardiol 2007;30:391-396. Go to original source... Go to PubMed...
    36. Anne B, Kendra K, Deborah M, et al. The Relationship between Body Mass Index and the Severity of Coronary Artery Disease in Patients Referred for Coronary Angiography. Cardiol Res Pract 2017;2017:5481671. Go to original source... Go to PubMed...
    37. Aksan G, Sinan İ, Gökay N, et al. Association of serum chemerin levels with the severity of coronary artery disease in patients with metabolic syndrome. Int J Clin Exp Med 2014;7:5461-5468.
    38. Lachine N, ElSewy F, Megallaa M, et al. Association between serum chemerin level and severity of coronary artery disease in Egyptian patients with type 2 diabetes. J Diabetol 2016;7:1-12. Go to original source...
    39. Xiaotao L, Xiaoxia Z, Yue X, Liye W. Serum chemerin levels are associated with the presence and extent of coronary artery disease. Coron Artery Dis 2012;23:412-416. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes